P
Patrick M. Lynch
Researcher at University of Texas Health Science Center at Houston
Publications - 136
Citations - 9339
Patrick M. Lynch is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 46, co-authored 136 publications receiving 9058 citations. Previous affiliations of Patrick M. Lynch include Creighton University.
Papers
More filters
Journal ArticleDOI
Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2
Wylie Burke,Mary B. Daly,Judy Garber,Jeffrey R. Botkin,Mary Jo Ellis Kahn,Patrick M. Lynch,Anne McTiernan,Kenneth Offit,Jeffrey M. Perlman,Gloria M. Petersen,Elizabeth J. Thomson,Claudette Varricchio +11 more
TL;DR: It is recommended that individuals considering genetic testing be counseled regarding the unknown efficacy of measures to reduce risk and that care for individuals with cancer-predisposing mutations be provided whenever possible within the context of research protocols designed to evaluate clinical outcomes.
Journal ArticleDOI
Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications
TL;DR: Because 40–60% of female patients will manifest endometrial cancer, tailored management is essential, and subtotal colectomy may be necessary, given the marked frequency of synchronous and metachronous CRC.
Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome
Noralane M. Lindor,Gloria M. Petersen,Donald W. Hadley,Anita Y. Kinney,Susan Miesfeldt,Karen H. Lu,Patrick M. Lynch,Wylie Burke +7 more
TL;DR: Burke et al. as mentioned in this paper published an article in JAMA that set forth recommendations for care of individuals with an inherited predisposition to hereditary nonpolyposis colorectal cancer (HNPCC).
Journal ArticleDOI
Microsatellite instability in the insulin–like growth factor II receptor gene in gastrointestinal tumours
Rhonda F. Souza,Rebecca Appel,Jing Yin,Suna Wang,Kara N. Smolinski,John M. Abraham,Tongtong Zou,Y. Q. Shi,Junyi Lei,John R. Cottrell,Karina Cymes,Kelli G. Biden,Lisa A. Simms,Barbara A. Leggett,Patrick M. Lynch,Marsha L. Frazier,Steven M. Powell,Steven M. Powell,Noam Harpaz,Haruhiko Sugimura,Joanne P. Young,Stephen J. Meltzer +21 more
TL;DR: Microsatellite instability in the insulin–like growth factor II receptor gene in gastrointestinal tumours is found to be a major cause of uncertainty in the prognosis of these tumours.
Journal ArticleDOI
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Robin K. S. Phillips,Marina Wallace,Patrick M. Lynch,Ernest T. Hawk,Gary B. Gordon,Brian P. Saunders,N. Wakabayashi,Yu Shen,Stuart O. Zimmerman,L. Godio,M. Rodrigues-Bigas,L-K. Su,Jeffrey W. Sherman,G. Kelloff,Bernard Levin,Gideon Steinbach +15 more
TL;DR: A panel of five endoscopists found a significant reduction in duodenal polyposis after six months of treatment with celecoxib 400 mg twice daily, suggesting COX-2 inhibition may help this otherwise untreatable condition.